LL-37 is the only cathelicidin-derived antimicrobial peptide found in humans, making it a rare and highly studied component of the innate immune system (Vandamme et al.). Unlike many antimicrobial peptides that serve only as pathogen killers, LL-37 has a dual role: it provides direct antimicrobial activity while also functioning as a regulator of immune responses (Yang et al.; Wong et al.). This combination makes it especially significant in research seeking to understand how the body simultaneously combats infection, controls inflammation, and initiates tissue repair (Amagai et al.).
The relevance of LL-37 extends beyond simple host defense. It has been implicated in conditions ranging from chronic skin and lung inflammation to wound healing and even cancer biology (Nurhikmah & Syah; Yang et al.). By linking antimicrobial defense with immune signaling and regeneration, LL-37 illustrates the complexity of peptides that sit at the interface between infection and immunity.
In this article, we will explore the structure and origin of LL-37, describe its mechanisms of action, and review the diverse research applications where it has been studied. By examining both its mechanisms and applications, we can better understand how LL-37 bridges antimicrobial defense, immune regulation, and tissue repair.
LL-37 is a 37–amino acid peptide generated from the cleavage of the precursor protein hCAP-18 (human cationic antimicrobial protein 18) (Méndez-Samperio). It is primarily expressed in immune cells such as neutrophils and macrophages, as well as in epithelial tissues including the skin, lungs, and gastrointestinal tract (Rivas-Santiago et al.; Sigurdardottir et al.).
As part of the innate immune system, LL-37 serves as an early-line defense molecule against infection. Its ability to integrate antimicrobial activity with immune regulation makes it distinct among naturally occurring peptides (Wan et al.).
LL-37 displays broad-spectrum activity against bacteria, viruses, and fungi. Its mechanism involves disrupting microbial membranes, leading to cell lysis. Unlike many conventional antimicrobials, LL-37’s cationic nature allows it to target negatively charged pathogen membranes while sparing host cells (Méndez-Samperio; Wan et al.)
Beyond killing pathogens, LL-37 regulates cytokine production and recruits immune cells to infection sites. It acts as a signaling molecule that bridges innate and adaptive immunity, influencing pathways of inflammation and immune tolerance (Sigurdardottir et al.; Strang et al.).
LL-37 also plays a role in tissue regeneration. It promotes keratinocyte migration, enhances re-epithelialization, and stimulates angiogenesis through growth factor signaling (Wong & Crawford; Raina et al.). This positions LL-37 as a peptide of interest in wound healing and tissue repair research.
LL-37 has been extensively investigated in the context of bacterial, viral, and fungal infections. Its broad-spectrum antimicrobial activity includes activity against drug-resistant bacteria such as Staphylococcus aureus and Pseudomonas aeruginosa (Neshani et al.; Nurhikmah & Syah). By directly disrupting microbial membranes, LL-37 bypasses many of the resistance mechanisms that compromise traditional antibiotics. In viral research, LL-37 has shown potential against enveloped viruses by interfering with viral entry and replication (Pahar et al.). These findings position LL-37 as an important molecule for exploring new strategies in infectious disease research.
Beyond infection, LL-37 is strongly implicated in the pathogenesis of several inflammatory disorders. Elevated LL-37 levels are found in conditions such as psoriasis, where it can trigger autoimmune-like responses by forming complexes with self-DNA (Baerveldt & Thio; Pahar et al.). Conversely, reduced levels are observed in diseases like atopic dermatitis, suggesting that its deficiency may contribute to impaired immune defense (Reinholz et al.). In respiratory research, LL-37 has been studied in chronic obstructive pulmonary disease (COPD) and asthma, where its ability to regulate cytokine production influences the severity of inflammation. This duality makes LL-37 a valuable peptide for investigating both protective and pathogenic aspects of immune regulation.
LL-37’s role in tissue repair has been demonstrated through its ability to promote keratinocyte migration, angiogenesis, and re-epithelialization. By stimulating growth factor release and enhancing cell migration, LL-37 accelerates the closure of wounds and supports the regeneration of damaged tissue (Nurhikmah & Syah; Pahar et al.). Its angiogenic activity, promoting the formation of new blood vessels, further aids in delivering nutrients and oxygen to healing sites. These properties highlight LL-37’s potential as a model peptide for understanding wound healing at the molecular level, particularly in the context of chronic wounds or impaired repair.
LL-37 exhibits a context-dependent role in oncology. In some cancer models, LL-37 acts as a pro-tumor factor by promoting cell proliferation, angiogenesis, and immune evasion. In other contexts, it has demonstrated anti-tumor activity, contributing to immune activation and inhibition of malignant cell growth (Baerveldt & Thio). The factors determining whether LL-37 acts in a pro- or anti-tumor capacity are still under investigation, with research pointing to differences in tissue type, tumor microenvironment, and receptor interactions. This complexity makes LL-37 a compelling subject for studies examining the fine balance between immune defense and tumor progression.
Antimicrobial peptides such as defensins and histatins are also part of the innate immune system. However, LL-37 is unique as the only cathelicidin in humans (Wong et al.; Méndez-Samperio). Compared to many AMPs, LL-37 has a stronger profile in immune modulation, extending its role beyond direct antimicrobial action (Vandamme et al.).
For a broader perspective on antimicrobial peptides, see our article:
Exploring the Therapeutic Applications of Antimicrobial Peptides.
The versatility of LL-37 continues to inspire new directions in peptide science:
To study LL-37’s mechanisms effectively, it is essential to use high-purity, research-grade peptides. Reliability and reproducibility in experiments depend on rigorous testing for identity, stability, and purity.
Polaris provides LL-37 peptide manufactured under strict quality standards. Researchers seeking to investigate LL-37’s antimicrobial, immune-modulatory, or tissue repair potential can obtain research-grade LL-37 from Polaris as a trusted source.
LL-37 peptide has a unique place in human biology as the only cathelicidin-derived antimicrobial peptide. Its ability to combine direct antimicrobial defense, immune regulation, and tissue repair functions makes it one of the most versatile molecules in innate immunity (Guerra et al.; Kuroda et al.). Research has shown its relevance across a wide spectrum of applications, from infection models and inflammatory disorders to wound healing and oncology, highlighting both its protective and context-dependent effects (Lu et al.).
What sets LL-37 apart from many other antimicrobial peptides is its broad functional range. Rather than acting solely as a pathogen killer, it also shapes immune responses and supports regeneration, demonstrating how a single peptide can influence multiple biological systems at once (Ramos et al.). This versatility has made it a focal point in studies of both acute and chronic disease.
As research expands, LL-37 is increasingly viewed not only as a marker of innate defense but also as a tool for exploring immune balance and tissue recovery. Synthetic analogs, peptidomimetics, and multi-peptide strategies may help overcome current challenges in stability and specificity, opening new possibilities for its use in experimental models (Converso et al.).
In summary, LL-37 represents a powerful link between defense, regulation, and repair, providing researchers with a window into how the innate immune system integrates these processes. Its ongoing study will continue to shape our understanding of immunity and may uncover new ways to model infection, inflammation, and regeneration in the laboratory.
Discount Applied Successfully!
Your savings have been added to the cart.
Join our Polaris Insiders program to get rewarded for loyalty with exclusive deals, news about upcoming products, and more.
You must be 21 years old or older in order to access our website. Please verify your age.
Our products are crafted for research and/or investigative purposes and are not suitable for direct human consumption or consumers, nor are they intended for clinical or therapeutic use. The statements and products listed on this website are not intended to diagnose, treat, cure, or prevent any disease.